Veracode Achieves Record Year with Significant Growth and Strategic Expansion
20.3.2025 13:50:00 EET | Business Wire | Press release
Veracode, a global leader in application risk management, today announced a milestone 2024, characterized by significant product innovation, strategic acquisitions, customer expansion, and industry recognition. The company’s customer base includes enterprises spanning technology, finance, insurance, public sector, and healthcare industries, including numerous Fortune 500 organizations.
"2024 has been transformative for Veracode," said Brian Roche, Chief Executive Officer at Veracode. "We've strengthened our capabilities through strategic acquisitions, enhanced our developer-centric experience, and delivered exceptional customer value. As organizations increasingly rely on open-source components and AI-generated code, they face unprecedented security risks from vulnerable dependencies and untrusted sources. We're partnering with organizations worldwide to address these emerging threats while reducing application risk across their entire software supply chain. Our momentum reflects the excellence of our team, our innovative solutions, and our unwavering commitment to customer success."
Driving Market Leadership Through Product Innovation and Expansion
Throughout the year, Veracode achieved significant product and market milestones that underscore its commitment to secure-by-design software development, through AI-powered innovation. Key highlights include:
- Enhanced Veracode Fix, combining AI and human expertise to reduce remediation time from months to minutes, empowering developers to fix vulnerabilities instantly across all integrated development environments.
- Acquisition of Longbow Security (now known as Veracode Risk Manager), expanding Application Security Posture Management (ASPM) capabilities.
- Early 2025 acquisition of technology from Phylum, strengthening open-source supply chain security to combat malicious packages in third-party code.
Exceptional Customer Growth and Return on Security Investment
Veracode’s market momentum accelerated with customer acquisition and retention globally. Over the past year, the company renewed 15 customers with an individual Annual Contract Value (ACV) exceeding $1 million and added hundreds of new customer logos. The launch of Veracode’s enhanced Velocity™ Partner Program contributed to this success through collaboration with partners including GuidePoint Security, Optiv, and Softcat, connecting Veracode’s portfolio with leading Fortune 100 companies worldwide.
Veracode’s total economic impact, a study conducted in August 2024 by Forrester Consulting, revealed that Veracode delivers a remarkable 184 percent return on investment, a net present value (NPV) of $4.6 million, and a payback period of less than six months for a $2 billion "composite organization."
"Every week, customers describe their expanding attack surface created by cloud technologies and the resulting risk management challenges," noted Roche. "We're helping CISOs at the intersection of security and business by rationalizing risks across cloud, code, and supply chains while ensuring compliance and business continuity. Unified visibility combined with contextualized prioritization and auto-remediation is the cornerstone of their success."
Strengthened Leadership and Global Expansion
Under the leadership of Brian Roche, who became Chief Executive Officer in April 2024, Veracode has bolstered its executive team with key appointments to drive growth and innovation. Recent additions welcomed Katie Kulikoski as Chief People Officer, David Wigglesworth as Chief Revenue Officer, and Karen Buffo as Chief Marketing Officer.
The company also expanded its global presence with enhanced regional and technical expertise. Sanjay Mandloi was appointed Senior Vice President of Engineering & Cloud Operations, Matt Katz joined as Vice President of Customer Success, Jean Janse van Vuuren joined as Vice President of EMEA & APAC, and Johnny Wong was promoted to Vice President of Global Solutions Architecture, leading the company’s pre-sales engineering teams globally. Jens Wessling also joined as Chief Technology Officer in the U.S., with the company’s Co-founder, Chris Wysopal, transitioning to a new role as Chief Security Evangelist.
Industry Recognition and Excellence
Veracode’s continued commitment to excellence was acknowledged with numerous awards and accolades in 2024. The company was recognized as a Gartner® Peer Insights™ Customers’ Choice for the fifth consecutive year, named a Strong Performer in The Forrester Wave™: Software Composition Analysis Software, Q4 2024, and ranked #1 ASPM product by PeerSpot. In addition, the company received multiple awards recognizing its products, dedicated team, and overall impact on the industry, including CRN Security 100 and The Boston ORBIE Award for Veracode’s CISO, Sohail Iqbal.
Looking Ahead: Veracode’s Vision for 2025
Veracode entered 2025 with a refreshed brand identity, and the company continues to focus on three strategic pillars:
- Unified visibility into application risks
- Real-time flaw remediation powered by AI
- Developer enablement to write secure code at business speed
"2024 was exceptional, but it's just the beginning," Roche concluded. "Our priority for 2025 is realizing our vision of secure code from inception. Our team's passion, expertise, and dedication will continue to propel us forward as we deliver even greater value to our customers worldwide as the trusted leader in application risk management."
About Veracode
Veracode is a global leader in Application Risk Management for the AI era. Powered by trillions of lines of code scans and a proprietary AI-assisted remediation engine, the Veracode platform offers adaptive software security and is trusted by organizations worldwide to build and maintain secure software from code creation to cloud deployment. Thousands of the world’s leading development and security teams use Veracode every second of every day to get accurate, actionable visibility of exploitable risk, achieve real-time vulnerability remediation, and reduce their security debt at scale. Veracode is a multi-award-winning company offering capabilities to secure the entire software development life cycle, including Veracode Fix, Static Analysis, Dynamic Analysis, Software Composition Analysis, Container Security, Application Security Posture Management, Malicious Package Detection, and Penetration Testing.
Learn more at www.veracode.com, on the Veracode blog, and on LinkedIn and X.
Copyright © 2025 Veracode, Inc. All rights reserved. Veracode is a registered trademark of Veracode, Inc. in the United States and may be registered in certain other jurisdictions. All other product names, brands or logos belong to their respective holders. All other trademarks cited herein are property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250320889134/en/
Contacts
Katy Gwilliam
kgwilliam@veracode.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom